Apolipoprotein E genotypes and the risk of Parkinson disease

Neurobiology of Aging

Volumn 32, Issue 11, 2011, Pages 2106.e1-2106.e6

  Gao, Jianjun ^a   Huang, Xuemei ^b   Park, Yikyung ^c   Liu, Rui ^a   Hollenbeck, Albert ^d   Schatzkin, Arthur ^c   Mailman, Richard B ^b   Chen, Honglei ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d AARP   (United States)

Author keywords

Apolipoprotein E (ApoE); Association; Dementia; Parkinson disease (PD)

Indexed keywords

APOLIPOPROTEIN E; CAFFEINE;

AGED; ALLELE; APOE EPSILON2 GENE; APOE EPSILON33 GENE; APOE EPSILON4 GENE; APOE GENE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DEMENTIA; DIETARY INTAKE; FAMILY HISTORY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GROUPS BY AGE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING;

EID: 80052627014     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.05.016     Document Type: Article

References (29)

1. Apolipoprotein E genotype in familial Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1997, 63:394-395. The French Parkinson's Disease Genetics Study Group.
2. Blázquez L., Otaegui D., Sáenz A., Paisán-Ruiz C., Emparanza J.I., Ruiz-Martinez J., Moreno F., Martí-Massó J.F., López de Munain A. Apolipoprotein E epsilon4 allele in familial and sporadic Parkinson's disease. Neurosci. Lett 2006, 406:235-239.
3. Chen H., Huang X., Guo X., Mailman R.B., Park Y., Kamel F., Umbach D.M., Xu Q., Hollenbeck A., Schatzkin A., Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010, 74:878-884.
4. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum cholesterol levels and the risk of Parkinson's disease. Am. J. Epidemiol 2006, 164:998-1002.
5. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
6. Elliott D.A., Kim W.S., Jans D.A., Garner B. Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neurosci. Lett 2007, 416:206-210.
7. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
8. Ghebremedhin E., Del Tredici K., Vuksic M., Rüb U., Thal D.R., Burbach G.J., Rosenberger A., Bickeböller H., Deller T., de Vos R.A., Jansen Steur E.N., Braak H. Relationship of apolipoprotein E and age at onset to Parkinson disease neuropathology. J. Neuropathol. Exp. Neurol 2006, 65:116-123.
9. Grupe A., Abraham R., Li Y., Rowland C., Hollingworth P., Morgan A., Jehu L., Segurado R., Stone D., Schadt E., Karnoub M., Nowotny P., Tacey K., Catanese J., Sninsky J., Brayne C., Rubinsztein D., Gill M., Lawlor B., Lovestone S., Holmans P., O'Donovan M., Morris J.C., Thal L., Goate A., Owen M.J., Williams J. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum. Mol. Genet 2007, 16:865-873.
10. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med 2002, 21:1539-1558.
11. Hu G., Antikainen R., Jousilahti P., Kivipelto M., Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008, 70:1972-1979.
12. Huang X., Abbott R.D., Petrovitch H., Mailman R.B., Ross G.W. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov. Disord 2008, 23:1013-1018.
13. Huang X., Chen P., Kaufer D.I., Tröster A.I., Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch. Neurol 2006, 63:189-193.
14. Huang X., Chen P.C., Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 2004, 62:2198-2202.
15. Hughes A.J., Daniel S.E., Lees A.J. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv. Neurol 1993, 60:595-599.
16. Mascitelli L., Pezzetta F., Goldstein M.R. Total cholesterol and the risk of Parkinson disease. Neurology 2009, 72:860.
17. Menzel H.J., Kladetzky R.G., Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983, 3:310-315.
18. Nicoll J.A., Roberts G.W., Graham D.I. Amyloid beta-protein, APOE genotype and head injury. Ann. N. Y. Acad. Sci 1996, 777:271-275.
19. Papapetropoulos S., Farrer M.J., Stone J.T., Milkovic N.M., Ross O.A., Calvo L., McQuorquodale D., Mash D.C. Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci. Lett 2007, 414:141-144.
20. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917:148-161.
21. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet 2007, 81:559-575.
22. Rea I.M., Mc Dowell I., McMaster D., Smye M., Stout R., Evans A. Apolipoprotein E alleles in nonagenarian subjects in the Belfast Elderly Longitudinal Free-living Ageing Study (BELFAST). Mech. Ageing Dev 2001, 122:1367-1372.
23. Schächter F., Faure-Delanef L., Guénot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat. Genet 1994, 6:29-32.
24. Schatzkin A., Subar A.F., Thompson F.E., Harlan L.C., Tangrea J., Hollenbeck A.R., Hurwitz P.E., Coyle L., Schussler N., Michaud D.S., Freedman L.S., Brown C.C., Midthune D., Kipnis V. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am. J. Epidemiol 2001, 154:1119-1125.
25. Simon K.C., Chen H., Schwarzschild M., Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007, 69:1688-1695.
26. Slooter A.J., Tang M.X., van Duijn C.M., Stern Y., Ott A., Bell K., Breteler M.M., Van Broeckhoven C., Tatemichi T.K., Tycko B., Hofman A., Mayeux R. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997, 277:818-821.
27. Stampfer M.J. Cardiovascular disease and Alzheimer's disease: common links. J. Intern. Med 2006, 260:211-223.
28. Weisgraber K.H., Mahley R.W. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 1996, 10:1485-1494.
29. Williams-Gray C.H., Goris A., Saiki M., Foltynie T., Compston D.A., Sawcer S.J., Barker R.A. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J. Neurol 2009, 256:493-498.